Kymos Acquires Germany’s Prolytic

Spanish contract laboratory company Kymos has boosted its European presence with the takeover of Germany’s Prolytic. Financial details were not disclosed.

The addition of the Frankfurt-based contract research organization has boosted Kymos’s activities in the biologics and advanced therapies market, also broadening its service offering to biopharmaceutical companies worldwide.

Kymos said the companies’ combined expertise will allow them to offer a unique selection of services for innovative small and large molecules, generics, biosimilars, antibodies, biomarkers, anti-drug antibodies, antibody-drug conjugates, hormones, enzymes and nucleic acids.

Interest in recombinant proteins and in advanced cell and gene therapies is booming, both in Europe and worldwide, said Kymos, pointing out that Prolytic also has experience in mRNA technologies, which are being used in Covid-19 vaccines currently under development in Europe.

“The knowledge that Prolytic has regarding DNA and RNA is a key scientific element of the advanced therapies services market that Kymos is entering,” said Joan Puig de Dou, CEO at Kymos. “The merger gives us the opportunity to increase our service offering, strengthen the emerging therapies market and create a multinational and multidisciplinary company.

Following the merger, Kymos now has three sites in Europe – Barcelona, Spain; Ancona, Italy; and Frankfurt, Germany.

Having strengthened its already prominent presence in Europe, Kymos said it now aims to expand into the Asia-Pacific region, while opening up promising new therapeutic areas.

 

Author: Elaine Burridge, Freelance Journalist

Dorothee Krone, managing director of Prolytic, and Joan Puig de Dou, CEO of...
Dorothee Krone, managing director of Prolytic, and Joan Puig de Dou, CEO of Kymos, sign the merger contract for Kymos and Prolytic to become Kymos Group. © Kymos Group

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.